Expanded collaboration to yield better biopharma entry to Personalis (NASDAQ:)’ MRD answer
FREMONT, Calif.–(BUSINESS WIRE)–Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) introduced in the present day that the businesses have expanded their business relationship. The businesses agreed in November 2023 to collaborate and produce ultra-sensitive MRD testing to market and launched their efforts on the 2024 American Society of Medical Oncology (ASCO) Annual Assembly. Tempus is serving because the unique business diagnostic accomplice for Personalis’ ultra-sensitive tumor-informed MRD product, NeXT Private ® Dx, for broad affected person adoption in breast and lung cancers, and for immunotherapy monitoring throughout all stable tumors.
Following a constructive response from the diagnostic market, the businesses have agreed to broaden their relationship to the biopharma business. Underneath this expanded relationship, Tempus will probably be enabled to supply Personalis’ NeXT Private MRD product to pharmaceutical and biotech clients who want to bundle MRD testing with different Tempus choices in a given examine.
Whereas we already provide NeXT Private by our personal biopharma channel, we’re happy to leverage Tempus’ built-in platform as nicely for these biopharma clients who want to mix NeXT Private with different Tempus merchandise, mentioned Chris Corridor, CEO of Personalis. We imagine the growth of the connection with Tempus will speed up market penetration of our main ultra-sensitive MRD platform and permit us to higher capitalize on the chance.
About Personalis, Inc.
At Personalis, we’re reworking the energetic administration of most cancers by breakthrough personalised testing. We purpose to drive a brand new paradigm for most cancers administration, guiding care from biopsy by the lifetime of the affected person. Our extremely delicate assays mix tumor-and-normal profiling with proprietary algorithms to ship superior insights at the same time as most cancers evolves over time. Our merchandise are designed to detect minimal residual illness (MRD) and recurrence on the earliest time factors, allow the collection of focused therapies primarily based on ultra-comprehensive genomic profiling, and improve biomarker technique for drug improvement. Personalis is predicated in Fremont, California. To study extra, go to www.personalis.com and join with us on LinkedIn and X, previously often called Twitter.
Ahead-Wanting Statements
This press launch incorporates forward-looking statements inside the that means of the Personal Securities Litigation Reform Act of 1995. All statements on this press launch that aren’t historic are forward-looking statements inside the that means of U.S. securities legal guidelines, together with statements referring to the attributes of or alternative for NeXT Private or the anticipated advantages of the expanded relationship with Tempus. Such forward-looking statements contain identified and unknown dangers and uncertainties and different elements which will trigger precise outcomes to vary materially from any anticipated outcomes or expectations expressed or implied by such statements, together with the dangers, uncertainties and different elements that relate to the success of Tempus’ gross sales and advertising and marketing efforts, together with the anticipated acceleration of the market penetration of NeXT Private. These and different potential dangers and uncertainties that would trigger precise outcomes to vary materially from the outcomes predicted in these forward-looking statements are described below the captions Danger Components and Administration’s Dialogue and Evaluation of Monetary Situation and Outcomes of Operations in Personalis’ Annual Report on Kind 10-Okay for the yr ended December 31, 2023, filed with the Securities and Change Fee (SEC) on February 28, 2024, its Quarterly Report on Kind 10-Q for the quarter ended March 31, 2024, filed with the SEC on Might 8, 2024, its Quarterly Report on Kind 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 7, 2024, and its Quarterly Report on Kind 10-Q for the quarter ended September 30, 2024, filed with the SEC on November 6, 2024. All info supplied on this launch is as of the date of this press launch, and any forward-looking statements contained herein are primarily based on assumptions that we imagine to be affordable as of this date. Undue reliance shouldn’t be positioned on the forward-looking statements on this press launch, that are primarily based on info obtainable to us on the date hereof. Personalis undertakes no responsibility to replace this info except required by legislation.
View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20241216417697/en/
Buyers:
Caroline Nook
buyers@personalis.com
415-202-5678
Media Contact:
Patrick Schmidt
pr@personalis.com
630-290-2787
Supply: Personalis, Inc.
